Vascular biology of coronary bypass grafts;Biologie vasculaire des greffons coronaires

Archives des Maladies du Coeur et des Vaisseaux

Volumn 97, Issue 12, 2004, Pages 1206-1215

  Barandon, L ^a,b   Kindo, M ^a,c   Perrault, L P ^a   Hebert, Y ^a   Cartier, R ^a   Bouchard, D ^a   Demers, P ^a   Page P ^d   Carrier, M ^a   Pellerin, M ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b INSERM   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROMA; BLOOD VESSEL GRAFT; CORONARY ARTERY BYPASS GRAFT; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERNAL MAMMARY ARTERY; REVIEW; SAPHENOUS VEIN; VASCULAR PATENCY; VEIN GRAFT;

ARTERIES; CORONARY ARTERY BYPASS; GRAFT OCCLUSION, VASCULAR; HUMANS; SAPHENOUS VEIN; VASCULAR PATENCY;

EID: 19944370428     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail 2001; 3: 283-91.
2. Delahaye F, Gevigney de G, Gaillard S et al. Epidémiologie et impact économique de l'insuffisance cardiaque en France. Arch Mal Cœur 1998; 9: 1307-14.
3. Loop FD, Lytle BW, Cosgrove DM et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986; 314: 1-6.
4. Bourassa MG. Long-term vein graft patency. Curr Opin Cardiol 1994; 9: 685-91
5. Hé GW. Arterial grafts for coronary artery bypass grafting: biological characteristics, functional classification, and clinical choice. Ann Thoroc Surg 1999; 67: 277-84.
6. Bryan AZ, Angelini GD. The biology of saphenous vein graft occlusion: etiology and strategies Tor prevention. Curr Opin Cardiol 1994; 9: 641-9.
7. Shah PJ, Gordon I, Fuller J et al. Factors affecting saphenous vein graft patency: clinical and angiographic study in 1402 symptomatic patients operated on between 1977 and 1999. J Thorac Cardiovasc Surg 2003; 126: 1972-7.
8. Powell JT, Gosling M. Molecular and cellular changes in vein grafts: influence or pulsatile stretch. Curr Opin Cardiol 1998; 13: 453-8.
9. Bryan AJ, Angelini GD. Vascular biology of coronary artery bypass conduits: new solutions to old problems? Adv Card Surg 1996; 8: 47-80.
10. Newby AC, George SJ. Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis. Curr Opin Cardiol 1996; 111: 574-82.
11. Moggio RA, Ding JZ, Smith CJ et al. Immediate-early gene expression in human saphenous veins harvested during coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1995; 110: 209-13.
12. Mavromatis K, Fukai T, Tate M et al. Early effects of arterial hemodynamic conditions on human saphenaus veins perfused ex vivo. Arterioscler Thromb Vasc Biol 2000; 20: 1889-95.
13. Shi Y, Patel S, Dayenpeck KL et al. Oxidative stress and lipid retention in vascular grafts: comparison between venous and arterial conduits. Circulation 2001; 103: 2408-13.
14. Cameran A, Davis KB, Green G et al. Coronary bypass surgery with internal-thoracic-artery grafts-effects on survival over a 15-year period. N Engl J Med 1996; 334: 216-9.
15. Loop FD. Internal-thoracic-artery grafts. Biologically better coronary arteries. N Engl J Med 1996; 334: 263-5.
16. van Son JA, Smedts F, Vincent JG et al. Comparative anatomic studies of various arterial conduits far myacardial revascularization. J Thorac Cardiavasc Surg 1990; 99: 703-7.
17. Liu ZG, Ge ZD, He GW. Difference in endothelium-derived hyperpolarizinq factor-mediated hyperpolarization and nitric oxide release Between human internal mammary artery and saphenous vein. Circulation 2000; 102: III296-III301.
18. He GW, Liu ZG. Comparison of nitric oxide release and endothelium-derived hyperpolarizing factor-mediated hyperpolarization between human radial and internal mammary arteries. Circulation 2001; 104: 1344-9.
19. Possati G, Gaudino M, Prati F et al. Long-term results of the radial artery used for myocardial revascularizatian. Circulation 2003; 108: 1350-4.
20. Chester AH, Amrani M, Borland JA. Vascular biology of the radial artery. Curr Opin Cardiol 1998; 13: 447-52.
21. Maniar HS, Barner HB, Bailey MS et al. Radial artery patency: are aortocoronary conduits superior to composite grafting? Ann Thorac Surg 2003; 76: 1498-503; discussion 1503-4.
22. Ochiai M, Ohno M, Taguchi J et al. Responses of human gastroepiploic arteries to vasoactive substances: comparison with responses of internal mammary arteries and saphenous veins. J Thorac Cardiovasc Surg 1992; 104: 453-8.
23. Tadikarimi S, O'Neil GS, Schyns C et al. Vasoconstrictor profile of the inferior epigastric artery. Ann Thorac Surg 1993; 56: 1090-5.
24. Tadjkarimi S, Chester AH, Borland JA et al. Endothelial function and vasodilator profile of the inferior epigastric artery. Ann Thorac Surg, 1994.58:207-10.
25. Gaudino M, Glieca F, Lyciani N et al. Clinical and angiographic effects af chronic calcium channel blocker therapy continued beyond first postoperative year in patients with radial artery grafts: results of a prospective randomized investigation. Circulation 2001; 104 (12 Suppl. 1): 164-167.
26. Rukosujew A, Reichelt R, Fabricius AM et al. Skeletonization versus pedicle preparation of the radial artery with and without the ultrasonic scalpel. Ann Thorac Surg 2004; 77: 120-5.
27. Cikirikcioglu M, Yasa M, Kerry Z et al. The effects of the Harmonic Scalpel on the vasoreactivily and endothelial integrity of the radial artery: a comparison of two different techniques. J Thorac Cardiavasc Surg 2001; 122: 624-6.
28. Mussa S, Guzik TJ, Black E et al. Comparative efficacies and durations of action of phenoxybenzamine, verapamil/nitroglycerin solution, and papaverine as topical antispasmodics for radial artery coronary bypass grafting. J Thorac Cardiovasc Surg 2003; 126: 1798-805.
29. Schussheim AE, Fuster V. Antithrombotic therapy and venous graft disease. Curr Opin Cardiol 1998; 13: 459-64.
30. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenaus-vein coronary-artery bypass grafts. The past coronary artery bypass graft trial investigators. N Engl J Med 1997; 336: 153-62.
31. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet 1997; 350: 389-96.
32. Knatterud GL, Rosenberg Y, Compeau et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels ond low-dose anticoagulotion in the post coronary artery bypass graft trial. Post CABG Investiqators. Circulation 2000; 102: 157-65.
33. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulqtion with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351: 233-41.
34. Huynh TP, Theraux P, Bogaty P et al. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 2001; 103: 3069-74.
35. Nalbone G, Bernot D, Peiretti F et al. Statins: maid-of-all-work in cardiovascular diseases! Arch Mol Cœur 2003; 96: 207-13.
36. Dotani MI, Elnicki DL, Jain AC et al. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000; 86: 1128-30, A6.
37. Chrislenson JT. Preoperative lipid control with simvastatin reduces the risk for graft failure afready 1 year after myocardial revascularization. Cardiovasc Surg 2001; 9: 33-43.
38. Werba JP, Tremoli E, Massirani P et al. Statins in coronary bypass surgery: rationale and clinical use. Ann Thorac Surg 2003; 76: 2132-40.
39. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
40. van Haelsf PL, Tervaert JW, van Geel PP et al. Long term angiotensin converting enzyme-inhibition in patients after coronary artery bypass grafting reduces levels of soluble intercellular cell adhesion molecule-1. Eur J Vasc Endovasc Surg 2003; 26: 387-91.
41. Oosterga M, Voors AA, Pinto YM et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol 2001; 87: 542-6.
42. Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. The MACB Study Group. Eur Heart J 1995; 16: 1825-32.
43. Chen J, Radford MJ, Wang Y et al. Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? Arch Intern Med 2000; 160: 947-52.
44. Cable DG, Caccitolo JA, Pearson PJ et al. New approaches to prevention and treatment of radial artery graft vasospasm. Circulation 1998; 98: II15-21; discussion II21-2.
45. Mangoush O, Nakamura K, AI-Ruzzeh S et al. Effect of ascorbic acid on endothelium-dependent vasodilatation of human arterial conduits for coronary artery bypass grafting. Eur J Cardiothorac Surg 2003; 24: 541-6.
46. Charlson ME, Isom OW. Clinical practice. Care after coronary-artery bypass surgery. N Engl J Med 2003; 348: 1456-63.
47. March KL, Patton BI, Wilensky RL et al. 8-Methoxypsoralen and longwave ultraviolet irradiation are a novel antiproliferative combination for vascular smooth muscle. Circulation 1993; 87: 184-91.
48. Ahn JD, Morishita R, Kaneda Y et al. Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ Res 2002; 90: 1325-32.
49. Mann MJ, Whittemore AD, Donaldson MC et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy, the PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354: 1493-8.
50. Dzau VJ, Mann MJ, Ehsan A et al. Gene therapy and genomic strategies for cardiovascular surgery: The emerging field of surgiamics. J Thorac Cardiovasc Sura 2001; 121: 206-16.
51. Keyes M, Dudek A, Jahagirdar B et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002; 109: 337-46.
52. Shintani S, Murohara T, Ikeda H et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103: 2776-9.
53. Jackson KA, Majka SM, Wang H et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001; 107: 1395-402.
54. Asahara T, Masuda H, Takahashi T et al. Bone marraw origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-8.
55. Assmus B, Schachinger V, Teupe C et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocarial Infarction (TOPCARE-AMI). Circulation 2002; 106: 3009-17
56. Griese DP, Ehsan A, Melo LG et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 2003; 108: 2710-5.